Aclarion, Inc. ACON shares are up Thursday after the company announced that on June 3 its Nociscan cost-effectiveness abstract was presented at the International Society for the Advancement of Spine Surgery.
What To Know: The abstract revealed that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.
"We are pleased with the cost-effectiveness abstract results," said Ryan Bond, chief strategy officer at Aclarion.
"We believe the results illustrating Nociscan's outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend; the value in healthcare."
Related Link: Micron Stock Is Trading Down Today: What's Going On?
ACON Price Action: Shares of ACON were up 15.5% at $1.20 at the time of publication, according to Benzinga Pro.
Image by Gerd Altmann from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
